首页 | 本学科首页   官方微博 | 高级检索  
     


Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin
Authors:Lu Jie  Murakami Masanao  Verma Subhash C  Cai Qiliang  Haldar Sabyasachi  Kaul Rajeev  Wasik Mariusz A  Middeldorp Jaap  Robertson Erle S
Affiliation:
  • a Department of Microbiology and the Tumor Virology Program, Abramson Comprehensive Cancer Center, School of Medicine, University of Pennsylvania, 202E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
  • b Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • c Department of Pathology, Cancer Center Amsterdam, Vrije Universiteit University Medical Center, 1081HV Amsterdam, The Netherlands
  • Abstract:Resistance to apoptosis is an important component of the overall mechanism which drives the tumorigenic process. EBV is a ubiquitous human gamma-herpesvirus which preferentially establishes latent infection in viral infected B-lymphocytes. EBNA1 is typically expressed in most forms of EBV-positive malignancies and is important for replication of the latent episome in concert with replication of the host cells. Here, we investigate the effects of EBNA1 on survivin up-regulation in EBV-infected human B-lymphoma cells. We present evidence which demonstrates that EBNA1 forms a complex with Sp1 or Sp1-like proteins bound to their cis-element at the survivin promoter. This enhances the activity of the complex and up-regulates survivin. Knockdown of survivin and EBNA1 showed enhanced apoptosis in infected cells and thus supports a role for EBNA1 in suppressing apoptosis in EBV-infected cells. Here, we suggest that EBV encoded EBNA1 can contribute to the oncogenic process by up-regulating the apoptosis suppressor protein, survivin in EBV-associated B-lymphoma cells.
    Keywords:EBNA1   Survivin   Sp1   Apoptosis   Oncogenic process
    本文献已被 ScienceDirect PubMed 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号